Protocol Ledger

NCT07361497 · Phase III · RECRUITING

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Interventional Phase III clinical trial protocol NCT07361497 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-16 Enrollment: 850 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07361497
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)850 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07361497
Protocol FieldVerified Registry Value
NCT IdentifierNCT07361497
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment850 participants (ESTIMATED)
Registered Start Date2026-03-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07361497
Hospital Research SiteLocationSite Profile
Medical Oncology Hematology Consultants PANewark, DEOpen Hospital Dossier ->
University of Chicago MedicineChicago, ILOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI